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Amyloid plaques are a pathological hallmark of Alzheimer’s disease. The major
component of these plaques are highly ordered amyloid fibrils formed by amyloid-β (Aβ)
peptides. However, whilst Aβ amyloid fibril assembly has been subjected to detailed and
extensive analysis in vitro, these studies may not reproduce how Aβ fibrils assemble
in the brain. This is because the brain represents a highly complex and dynamic
environment, and in Alzheimer’s disease multiple cofactors may affect the assembly of
Aβ fibrils. Moreover, in vivo amyloid plaque formation will reflect the balance between the
assembly of Aβ fibrils and their degradation. This review explores the roles of microglia
as cofactors in Aβ aggregation and in the clearance of amyloid deposits. In addition, we
discuss how infection may be an additional cofactor in Aβ fibril assembly by virtue of the
antimicrobial properties of Aβ peptides. Crucially, by understanding the roles of microglia
and infection in Aβ amyloid fibril assembly it may be possible to identify new therapeutic
targets for Alzheimer’s disease.
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INTRODUCTION
Alzheimer’s disease (AD) is the most common form of dementia and is characterized by brain
atrophy, amyloid plaques, intracellular neurofibrillary tangles, and neuroinflammation (Braak and
Braak, 1991; Jack et al., 1998; Heppner et al., 2015). The amyloid plaques are primarily composed
of fibrils formed by the β-amyloid (Aβ) peptides (Wang et al., 1996). In AD Aβ assembles into
fibrils within the highly complex environment of the brain; as such multiple molecular and cellular
factors may influence not only the formation the fibrils, but also their clearance. In contrast, Aβ
fibril formation is typically studied in vitro by incubating the purified peptide in simple solution
conditions. This may not reproduce how Aβ fibrils assemble in the AD brain, and result in the
generation of fibrils that have different properties to those formed in vivo. Indeed, Aβ fibrils made
in vitro do not efficiently induce amyloid plaque formation when injected into the hippocampus of
young AD model mice, whereas brain extracts from AD patients and aged AD model mice lead to
Aβ deposition into plaques (Meyer-Luehmann et al., 2006). This suggests that there are cofactors
present in vivo that promote Aβ fibril assembly and deposition in AD. This review will focus on two
potential cofactors, microglia and infection, and how these modulate Aβ amyloid fibril assembly
and whether these can be targeted to reduce plaque formation (Figure 1).
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Aβ AMYLOID FIBRIL ASSEMBLY
Aβ is formed by the sequential cleavage of transmembrane
protein amyloid precursor protein (APP) by β-secretase and
γ-secretase, resulting in Aβ fragments ranging from 39 to 43
residues in length (Selkoe, 1998). The predominant forms of
the peptide are the 40- and 42- residue peptide variants Aβ1−40
and Aβ1−42 (Wang et al., 1996). All known dominant mutations
associated with early-onset AD occur in APP or in presenilin-
1 (PSEN1) and presenilin-2 (PSEN2), which are components
of γ-secretase (Karch et al., 2014). Genome-wide association
studies (GWAS) have also been used to identify genetic risk
factors for late-onset AD, and this has identified genes that
encode proteins involved in APP processing including SORL1,
ADAM10, and APH1B (Lambert et al., 2013; Jansen et al.,
2019). This genetic evidence implicates Aβ as an initiating
factor in AD.
Aβ peptides are intrinsically disordered in their monomeric
form and assemble into highly ordered fibrils via a nucleation
dependent pathway, in which monomers self-associate to form
a nucleus (Knowles et al., 2014). Addition of further Aβ peptides
to the nucleus culminates in the formation of fibrils, which can
then be elongated by end on addition of Aβ peptides. An array
of oligomeric forms of Aβ are associated with fibril assembly
reactions and many studies point to a key role for these oligomers
in neurotoxicity (Shankar et al., 2008; Evangelisti et al., 2016;
Serra-Batiste et al., 2016). In addition, in secondary nucleation,
the surface of existing Aβ fibrils can catalyze the formation
of new Aβ fibrils (Cohen et al., 2013). Cross-seeding can also
occur in which other protein complexes, including fibrils of other
amyloidogenic sequences, provide surfaces for the secondary
nucleation of Aβ fibril assembly (Morales et al., 2013; Ono et al.,
2014; Moreno-Gonzalez et al., 2017).
Aβ amyloid fibrils are highly ordered, with a common
cross-β structure, consisting of β-sheets in which in-register
β-strands are oriented perpendicularly to the fibril axis, with
4.6–4.7 Å spacing between them (Eanes and Glenner, 1968).
Fibrils are unbranched, typically 5–15 nm in width, can reach
up to several microns in length and can consist of a number
of cross-β subunits (Iadanza et al., 2018). These subunits are
protofilaments which associate to form a mature Aβ fibril
(Iadanza et al., 2018). While all Aβ fibrils share this characteristic
cross-β structure, polymorphism refers to the different molecular
structure of the peptide within this cross-β subunit, and also
the different number and arrangement of the cross-β subunits
that make up a mature fibril (Tycko, 2015). While Aβ fibrils
formed both in vitro and derived from ex vivo patient tissue
exhibit polymorphism, the structures determined to date of
fibrils derived from AD patient tissue are distinct from those
formed in vitro (Petkova et al., 2005; Paravastu et al., 2008,
2009; Lu et al., 2013; Qiang et al., 2017; Kollmer et al.,
2019). In addition, it was shown that synthetic Aβ fibrils do
not efficiently induce Aβ-plaque formation when injected into
the hippocampus of young AD model (APP23) mice, whereas
brain extracts from AD patients and aged APP23 mice led to
Aβ deposition (Meyer-Luehmann et al., 2006). This suggests
that a cofactor, or multiple cofactors within the brain, could
be required to drive Aβ assembly and deposition in vivo
(Meyer-Luehmann et al., 2006).
MICROGLIA AND THE IMMUNE
RESPONSE TO Aβ AMYLOID FIBRILS
Microglia are immune cells that are resident in the brain,
and depending on the region, make up 0.5–16% of all cells
in the human brain (Mittelbronn et al., 2001; Ajami et al.,
2007; Ginhoux et al., 2010). When in a resting state, microglia
have a ramified morphology, multiple fine processes project
from the cell body, which are used to monitor the central
nervous system (CNS) microenvironment (Nimmerjahn et al.,
2005). These cells respond to changes in the local environment
and migrate to activating stimuli, adopting a more amoeboid
morphology and expressing an altered repertoire of receptors
(Davalos et al., 2005). Reactive microglia are observed in AD
brains, in close association with Aβ plaques (Itagaki et al., 1989;
Yuan et al., 2016). Aβ fibrils have been shown to activate the
production of pro-inflammatory cytokines by microglia and
thus may be a stimulus for the increased production of these
cytokines, which contribute to the neurodegeneration associated
with AD (Griffin et al., 1989; Bauer et al., 1991; Patel et al., 2005;
Halle et al., 2008; Ojala et al., 2009). However, in addition to
cytokine production, microglia may also modulate the formation
of Aβ amyloid fibrils and plaques. Crucially, microglia can
affect both the generation and the degradation of Aβ fibrils.
The balance between these activities may therefore represent
a key determinant in whether amyloid plaques accumulate
in the AD brain.
FORMATION OF PHYSICAL BARRIERS
AROUND Aβ AMYLOID PLAQUES BY
MICROGLIA
In AD microglia migrate to, surround and infiltrate Aβ amyloid
plaques, where they come into close contact with Aβ fibrils
(Itagaki et al., 1989). In AD mice models this recruitment
can occur as quickly as within a day of plaque formation
and results in a two-fivefold increase in microglia at Aβ
plaques compared to the neighboring tissue (Frautschy et al.,
1998; Simard et al., 2006; Meyer-Luehmann et al., 2008).
Microglia have been shown to surround plaques forming a
barrier that limits their outward growth by preventing the
recruitment of Aβ peptides (Condello et al., 2015). Plaques with
less microglial coverage were less compact and had increased
recruitment of soluble Aβ1−42, allowing the formation of Aβ1−42
protofibrils (Condello et al., 2015). Similar results were found
after depletion of microglia with PLX5622, an inhibitor of
the essential microglial colony stimulating factor 1 receptor
(CSF1R) signaling pathway (Spangenberg et al., 2019). These
hotspots of Aβ1−42 protofibrils were found to be neurotoxic,
resulting in more severe neuritic dystrophy (Condello et al.,
2015). This supports the role of microglia in the formation
of a physical barrier around fibrillar plaques, compacting
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FIGURE 1 | Modulation of Aβ amyloid fibril assembly and clearance by microglial cells and infection, and potential targets of intervention. Aβ peptide assembles into
highly ordered amyloid fibrils with a characteristic cross-β structure. These fibrils form the core of amyloid plaques present in AD brains. Microglia surround these
plaques, forming a protective barrier around them, limiting the recruitment of further Aβ. Microglia can also contribute to the clearance of Aβ fibrils. In order to remove
Aβ deposits in AD, the phagocytic activity of microglia could be enhanced by targeting receptors and pathways involved in this response, such as TREM2 and
CD33. Increasing the breakdown by microglial proteases could also enhance clearance of Aβ deposits. The NLRP3 inflammasome in microglia is concurrently
activated in response to Aβ fibrils, resulting in the release of ASC specks. These specks cross-seed the formation of Aβ fibrils, resulting in further Aβ aggregation.
Therefore, inhibiting the activation of the NLRP3 inflammasome would reduce the cross seeding of Aβ aggregation by ASC specks. Aβ also has antimicrobial and
antiviral-properties, assembling into amyloid fibrils in response to infection. Thus, infection could be targeted to reduce Aβ aggregation.
plaque cores, limiting growth and reducing neurite dystrophy
(Condello et al., 2015).
An array of genes is associated with the development of
late-onset AD (Karch et al., 2014; Jansen et al., 2019). One of
these genes encodes triggering receptor expressed on myeloid
cells 2 (TREM2), an immune receptor of the immunoglobulin
family, which is expressed by microglia (Lambert et al., 2013).
TREM2 sequence variants R47H and R62H have been found
to increase the risk of developing late-onset AD (Jonsson
et al., 2013; Chih Jin et al., 2014). This plasma membrane
receptor forms signaling complexes with the adaptor protein
DNAX-activating protein of 12 kDa (DAP12), and is important
in the phagocytosis of apoptotic neurons and the negative
regulation of inflammatory responses (Hamerman et al., 2005,
2006; Takahashi et al., 2005; Piccio et al., 2007; Hsieh et al.,
2009). In AD model mice, the deletion of TREM2 did not
significantly affect Aβ deposition, but it did reduce the extent
to which microglia surrounded Aβ plaques (Ulrich et al., 2014;
Wang et al., 2016). Plaques were more diffuse, and this was
associated with an increased level of neuritic damage. This
suggests a requirement for TREM2 in the formation of a
neuroprotective microglial barrier. In support of this role for
TREM2, Yuan et al. (2016) found that mice haplodeficient for
TREM2 or DAP12 and humans harboring the R47H TREM2
mutation had a reduced microglial barrier surrounding Aβ
plaques, and reduced plaque compaction. The Aβ fibrils in
these plaques were found to be longer and there was more
evidence of Aβ nanostructures extending out from the main
Aβ fibril bundle, allowing more interaction with nearby neurites
(Yuan et al., 2016).
CLEARANCE OF Aβ BY MICROGLIA
In addition to surrounding amyloid plaques, the microglia
recruited to these plaques may be involved in clearing these
amyloid deposits (Rogers et al., 2002). Microglia are thought
to contribute to the clearance of Aβ via the secretion of
amyloid-degrading enzymes and by the internalization of Aβ
fibrils. Furthermore, analysis of gene regulatory networks in
late-onset AD identified that immune and microglial molecular
networks were most associated with late-onset AD (Zhang
et al., 2013). A number of these risk genes have been found
to be involved in the clearance of Aβ (Kleinberger et al.,
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2014; Ulrich et al., 2018; Griciuc et al., 2019) highlighting the
importance of this process in AD.
Secreted Microglial Proteases
Enzymes that cleave Aβ include the metalloendopeptidases
insulin-degrading enzyme (IDE) and neprilysin (NEP). Microglia
are thought to contribute to the secretion of these enzymes,
along with neurons and astrocytes, and a decrease in microglial
expression of both enzymes is associated with aging in AD model
mice (Leissring et al., 2003; Hickman et al., 2008; Tamboli et al.,
2010). These enzymes, however, are thought to be limited to the
degradation of monomeric peptide, and do not contribute to
the degradation of Aβ amyloid fibrils (Qiu et al., 1998; Farris
et al., 2003; Leissring et al., 2003). There is also evidence on
the capability of NEP to degrade some oligomeric forms of
Aβ. The enzyme was found to degrade oligomers formed from
synthetic Aβ peptide, but in another study NEP did not degrade
Aβ oligomers secreted from cells overexpressing APP (Kanemitsu
et al., 2003; Leissring et al., 2003).
Secreted enzymes capable of cleaving fibrillar Aβ have,
however, been identified. Metalloprotease-9 (MMP-9) is a zinc-
dependent metalloprotease expressed by neurons, astrocytes,
microglia and vascular cells in the brain (Vafadari et al., 2016).
It was shown that incubation of Aβ1−40 and Aβ1−42 fibrils
with MMP-9 leads to their degradation (Yan et al., 2006). Fibril
fragments produced were analyzed using mass spectrometry
and this revealed species corresponding to Aβ1−20 and Aβ1−30,
suggesting Phe20-Ala21 and Ala30-Ile31 as cleavage sites (Yan
et al., 2006). These sites must be accessible to MMP-9 in the fibril
structure. MMP-9 was also found to degrade compact Aβ amyloid
plaques in brain sections from AD model (APP/PS1) mice (Yan
et al., 2006). MMP-2 is implicated in the degradation of soluble
Aβ, with increased Aβ1−40 and Aβ1−42 identified in the soluble
fraction of cortex and hippocampal brain samples of knock out
MMP-2 mice compared to wild-type controls (Yin et al., 2006).
Uptake and Degradation of Aβ Fibrils by
Microglia
Consistent with a role in the clearance of Aβ, microglia express
an array of receptors that facilitate the uptake of Aβ aggregates.
Toll-Like Receptors
One family of receptors involved in the immune response
to Aβ amyloid are the Toll-like receptors (TLRs) a class of
pattern recognition receptors that recognize conserved microbial
structures (Kawasaki and Kawai, 2014). TLRs are type I integral
membrane proteins which recognize ligands with their leucine-
rich repeat (LRR)-containing ectodomains. RNA sequencing
revealed that the expression of six TLR genes (1,2,4,5,6,8)
is upregulated in the temporal cortex of AD patients when
compared to control brains, likely resulting from increased
microglial activation (Chakrabarty et al., 2018). A direct
interaction was identified between Aβ fibrils and CD14, a TLR co-
receptor previously shown to associated with the inflammatory
response to fibrillar Aβ (Fassbender et al., 2004; Reed-Geaghan
et al., 2009). This interaction was shown to facilitate the
internalization of Aβ fibrils by microglia, at lower concentrations
than that required for cell activation (Liu et al., 2005). This
suggests that CD14 could be involved in the phagocytosis of
Aβ fibrils at low concentrations, but increased Aβ levels in AD
results in cellular activation. Consistent with a role in Aβ uptake,
TLR4 deficiency in AD mouse models results in increased fibrillar
and soluble Aβ deposition (Tahara et al., 2006). Conversely,
stimulation of the murine microglial cell line BV-2 with TLR2
and TLR4 ligands significantly increased the internalization of
Aβ in vitro, further implicating TLR receptors in Aβ uptake and
clearance (Tahara et al., 2006; Song et al., 2011).
Scavenger Receptors
Another family of receptors found to be involved in the
internalization of Aβ fibrils are the scavenger receptors (SRs),
which are highly expressed by microglia (Christie et al., 1996;
Wilkinson and El Khoury, 2012). It was found initially that class
A SRs, characterized by an extracellular collagen-like domain, are
involved in the binding to Aβ fibrils to microglial cells (El Khoury
et al., 1996). It was then shown that coincubation of microglia
with SR ligands such as acetyl-low density lipoprotein (Ac-LDL)
reduced Aβ uptake, and CHO cells transfected with class A, or
class B SR’s showed enhanced Aβ uptake, suggesting that SRs
are important in the uptake and clearance of Aβ (Paresce et al.,
1996). Further investigation using microglia that are deficient in
SR-A1 confirmed the role of SR-A1 and also SR-B1 in binding
Aβ fibrils, consistent with a role in the clearance of Aβ amyloid
(Husemann et al., 2001). CD36 is a class B scavenger receptor
identified to form a receptor complex with the α6β1-integrin and
the integrin-associated protein CD47 in microglia. This complex
was shown to mediate the binding of Aβ fibrils to microglial
cells and the subsequent activation of intracellular signaling
pathways (Bamberger et al., 2003). While initial studies reported
that Aβ fibril binding to this complex is largely involved in the
activation of an inflammatory response, it was also reported that
the interaction of Aβ fibrils with this complex is involved in the
phagocytic uptake of fibrils by microglia (Coraci et al., 2002;
Moore et al., 2002; Bamberger et al., 2003; Koenigsknecht and
Landreth, 2004).
TREM2
The deletion of TREM2 in primary microglia was shown to
significantly reduce the phagocytosis of aggregated Aβ1−42
(Kleinberger et al., 2014). Similarly, TREM2 deficiency reduced
the efficacy of antibody-targeted Aβ phagocytosis by microglia
(Xiang et al., 2016). There is evidence for direct interactions
between TREM2 and Aβ1−42 fibrils, although no difference in
binding affinity was identified for TREM2 R47H and R62H
variants that are associated with an increased risk of AD (Lessard
et al., 2018). However, the internalization of monomeric Aβ
was reduced with the expression of these TREM2 AD variants
(Lessard et al., 2018). In another study, TREM2 was found to bind
to Aβ oligomers with a similar affinity to previously described
Aβ receptors, CD36 and receptor for advanced glycation end
products (RAGE), and this interaction was compromised by
R47H and R62H TREM2 mutations (Zhao et al., 2018). In this
study, TREM2 deficiency had little effect on Aβ uptake but led
to significantly reduced Aβ degradation once internalized by
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microglia (Zhao et al., 2018). In TREM2 knock out mice injected
with Aβ oligomers, there was reduced microglial migration to
the site of injection and reduced Aβ clearance (Zhao et al.,
2018). A recent study found that loss of TREM2 function led
to an acceleration in early amyloidogenesis, accompanied by
a reduction in microglial recruitment as previously described,
again suggesting that TREM2 has a role in microglial clearance of
Aβ (Parhizkar et al., 2019). Together this evidence suggests that
Aβ is a ligand for TREM2, and that TREM2 has a role to play in
both Aβ clearance and Aβ-stimulated microglial activation.
A Novel Role for the Autophagy
Machinery in Aβ Receptor Recycling
Aβ clearance by microglia may involve proteins of the autophagy
machinery in a pathway distinct from their canonical function
(Heckmann et al., 2019). This pathway is referred to as LC3-
associated endocytosis (LANDO), with LC3 being a key protein
in macroautophagy. Evidence from this study suggests that
LANDO facilitates recycling of the Aβ receptors CD36, TLR4
and TREM2, thus allowing cycles of Aβ endocytosis to continue,
promoting Aβ uptake and clearance (Heckmann et al., 2019).
The autophagy proteins ATG5 and Rubicon were found to be
protective against Aβ deposition, with their absence leading
to increased pathology. The expression of autophagy proteins
declines with age, which may be related to the development of
Aβ pathology in AD (Rubinsztein et al., 2011). It is important
to note that macroautophagy has previously been implicated
in the secretion of Aβ into the extracellular space where it
forms plaques in AD (Nilsson et al., 2013). When autophagy-
related gene 7 (ATG7) was conditionally knocked out in
excitatory neurons of APP transgenic mice, extracellular Aβ
plaque pathology was significantly decreased, and Aβ instead
accumulated intracellularly (Nilsson et al., 2013). Thus, a
reduction in expression of proteins involved in macroautophagy
could affect both Aβ secretion and clearance.
CD33
CD33, a type 1 transmembrane protein, is a sialic acid-binding
immunoglobulin-like lectin (Siglec) expressed by immune cells,
and was identified by GWAS to be associated with AD
(Hollingworth et al., 2011). In addition, CD33-positive microglia
and CD33 protein levels were found to be increased in AD
brains, and CD33 was found to be associated with cognitive
decline (Karch et al., 2012; Griciuc et al., 2013). It was found
that a rs3865444 allele that was found to be protective in AD
led to a reduction in the level of insoluble Aβ in the AD brain,
suggesting a role for CD33 in mediating the clearance of Aβ
(Griciuc et al., 2013). Furthermore, a risk allele of rs3865444
was associated with reduced Aβ1−42 internalization, and an
increase in fibrillar amyloid, and neuritic amyloid pathology
in AD patients, supporting the involvement of CD33 in the
modulation of Aβ clearance (Bradshaw et al., 2013). Recent work
by Griciuc et al. (2019) showed that knockout of CD33 led to
mitigated Aβ pathology in 5xFAD AD model mice, with genes
related to phagocytosis found to be upregulated (Griciuc et al.,
2019). The opposite effects were found to result from TREM2
knockout (Griciuc et al., 2019). Interestingly, this differential gene
expression in CD33 deficient 5xFAD mice only occurred in the
presence of TREM2, suggesting that TREM2 acts downstream of
CD33 (Griciuc et al., 2019).
Degradation of Aβ Fibrils by Lysosomal
Proteases
Once internalized Aβ fibrils are sorted to lysosomes, a degradative
organelle which contains proteases that are capable of degrading
Aβ fibrils (Paresce et al., 1997). Aβ1−42 monomeric peptide,
non-fibrillar assemblies and fibrils were all shown to be cleaved
by the lysosomal cysteine protease cathepsin B, resulting in the
production of Aβ1−40, Aβ1−38 and Aβ1−33 in a dose-dependent
manner (Mueller-Steiner et al., 2006). This suggests an anti-
amyloidogenic role for cathepsin B, via the C-terminal truncation
of Aβ. In addition to this, cathepsin B was found to accumulate in
mature amyloid plaques in AD model mice. Cathepsin B activity
was highest in supernatant taken from primary microglial cell
cultures, compared to neurons and astrocytes, suggesting that
these cells act as a source of cathepsin B as they surround Aβ
plaques (Mueller-Steiner et al., 2006). The lysosomal protease,
tripeptidyl peptidase 1 (TPP1) is another enzyme capable of
cleaving Aβ fibrils. Digestion of Aβ1−42 fibrils in vitro by TPP1
revealed a number of different cleavage sites within the β-sheet
domains, and molecular dynamics simulations demonstrated
that these cleavages lead to destabilization of the β-sheet fibril
structure (Solé-Domènech et al., 2018).
Failure of Microglia to Clear Aβ Amyloid
Fibrils in AD
Although evidence suggests that Aβ amyloid fibrils can be
internalized by microglia and degraded by lysosomal and secreted
proteases, microglia may be limited in their capacity to clear
Aβ. This is evidenced by the accumulation of amyloid plaques
in the AD brain despite microglial recruitment. A number of
studies support this notion (Paresce et al., 1997; Majumdar et al.,
2008). Fluorescently labeled Aβ fibrils internalized by cultured
microglia were trafficked to lysosomes, however, Aβ was not
degraded and was retained in microglial cells over a 3-day chase
period (Majumdar et al., 2008). This was due to the inefficient
delivery of chloride transporter CIC-9 to lysosomes, resulting
in incomplete lysosome acidification and reduced activity of
lysosomal proteases in the microglial (Majumdar et al., 2011).
Similarly, the genetic risk factor for AD, the ε4 allele of ApoE,
may impair the ability of microglia to remove Aβ deposits. ApoE
is a key cholesterol carrier, primarily produced by astrocytes in
the brain, but also to some extent by microglia, and facilitates the
transport of lipids via receptors of the low-density lipoprotein
receptor (LDLR) family (Bu, 2009). Three common isoforms of
ApoE exist in humans; ε2 ε3 and ε4 (Mahley, 1988). The ε4
allele of ApoE is the strongest genetic risk factor for late-onset
AD, whereas the ε2 allele has a protective effect (Lambert et al.,
2013). ApoE deletion in AD mouse models leads to reduced
Aβ plaque deposition, implicating ApoE in Aβ amyloidogenesis
and/or clearance (Bales et al., 1997; Ulrich et al., 2018). The
efficiency of soluble Aβ clearance from the interstitial fluid of the
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brain is dependent on the ApoE isoform, with ApoE4 resulting in
the least efficient clearance (Castellano et al., 2011). A number
of mechanisms by which ApoE influences Aβ clearance have
been proposed. In microglia, it was reported that lipidated
forms of ApoE stimulate the degradation of soluble Aβ by
NEP, with ApoE4 being the least efficient at promoting this
degradation, and ApoE2 having the strongest effect (Jiang et al.,
2008). There is also evidence to suggest that ApoE results in
faster delivery of Aβ to lysosomes in microglia, by lowering
cellular cholesterol levels, and the efficiency of this cholesterol
efflux activity is isoform-dependent (Hara et al., 2003; Lee et al.,
2011). Furthermore, microglial-like cells derived from human
induced pluripotent stem cells expressing ApoE4 displayed
reduced oligomeric Aβ1−42 phagocytosis compared to ApoE3
cells (Lin et al., 2018).
The ability of microglia to clear amyloid deposits in AD
may also be diminished as a consequence of aging. Indeed,
when production and clearance rates of Aβ1−40 and Aβ1−42
were tracked in AD patients using metabolic labeling, it was
found that clearance rates for both peptides were reduced in
AD compared to controls, but there were no differences in the
rates of their production (Mawuenyega et al., 2010). This may be
due to a reduced capacity of microglia to internalize Aβ fibrils.
Microglia from older AD model mice have a twofold to sixfold
reduction in expression of Aβ-binding receptors SR-A, CD36 and
RAGE compared to wild type controls, in addition there was a
significant reduction in the expression of secreted Aβ-degrading
enzymes IDE, NEP and MMP-9 (Hickman et al., 2008). Old
AD model mice were also found to have increased expression
of inflammatory cytokines tumor necrosis factor-α (TNF-α) and
interleukin-1β (IL-1β), indicating that while clearance pathways
are impaired, a damaging inflammatory response to Aβ could be
exacerbated (Hickman et al., 2008). A later study also found an
impairment in phagocytic activity in AD mice compared to wild
type controls, and this impairment correlated with an increased
deposition of Aβ (Krabbe et al., 2013). Reducing Aβ load
by administering an anti-Aβ antibody restored the phagocytic
capacity of microglia, suggesting that the microglial dysfunction
is a result of AD pathology (Krabbe et al., 2013).
A number of subset populations of microglia have been
identified in aging and AD brains, with distinct transcriptional
profiles and phenotypes (Keren-Shaul et al., 2017; Krasemann
et al., 2017; Marschallinger et al., 2020). These include ‘damage
associated microglia’ (DAM) which are proposed to play a
protective role in disease (Keren-Shaul et al., 2017), and microglia
with a neurodegenerative phenotype, which have lost their
homeostatic function (Krasemann et al., 2017). The switch of
microglia to this impaired neurodegenerative phenotype was
found to be dependent on APOE signaling induced by TREM2,
further implicating these pathways and microglial dysfunction in
AD (Krasemann et al., 2017). Furthermore, a unique population
was recently identified in the aging brain, termed ‘lipid-droplet-
accumulating microglia’ (LDAM), which show a build-up of
lipid droplets, and possess a distinct transcriptional signature
(Marschallinger et al., 2020). Importantly, these microglia show
defects in phagocytosis, as well as increased release of pro-
inflammatory cytokines (Marschallinger et al., 2020). LDAM
accounted for up to 50% of microglia in the hippocampus
of aged mice, but have yet to be confirmed in AD models
or brains (Marschallinger et al., 2020). Frigerio et al. (2019)
showed that a microglial population termed ‘activated response
microglia’ (ARMs) occur naturally in aging mice and in human
brain, but the conversion to this state is accelerated in response
to Aβ plaques (Frigerio et al., 2019). A number of AD
risk genes including ApoE were found to be upregulated in
ARMs, conversely depletion of ApoE blocked the recruitment
of microglia to Aβ plaques (Frigerio et al., 2019). Given the
association of the ApoE4 allele with AD, future studies should
investigate whether this allele influences the production of ARMs
(Lambert et al., 2013). Nonetheless, the implication of these data
is that both aging and AD affect the phenotypes of microglia and
thus their responses to Aβ.
CLEARANCE OF Aβ BY ASTROCYTES
In addition to microglia, astrocytes may play a role in the
clearance of Aβ. Astrocytes, the most abundant glial cell in the
brain, have numerous crucial roles in maintaining and regulating
neuronal function and signal transmission (Perez-Nievas and
Serrano-Pozo, 2018). Like microglia, astrocytes can react to
pathogenesis by adopting a reactive phenotype, and this reactive
astrogliosis is observed in AD brains, with a close relationship
to Aβ pathology (Itagaki et al., 1989; Nagele et al., 2003; Perez-
Nievas and Serrano-Pozo, 2018). Moreover, astrocytes may also
contribute to the clearance of Aβ fibrils in AD and as discussed
above the secreted protease MMP-9 is produced by a number of
cell types including astrocytes (Vafadari et al., 2016). Astrocytes
also secrete the MMP membrane type-1 (MT1) and kallikrein-
related peptidase 7 (KLK7) (Liao and Van Nostrand, 2010; Kidana
et al., 2018). MT1 is expressed by reactive astrocytes close to
Aβ deposits and was shown to degrade Aβ plaques in an AD
(APP) mouse model and cleave Aβ1−42 fibrils in vitro (Liao
and Van Nostrand, 2010). KLK7 was found to cleave Aβ in the
hydrophobic core motif of fibrils (KLVFFA), thus preventing
fibril formation and promoting the degradation of pre-formed
fibrils (Shropshire et al., 2014). KLK7 shows Aβ-degrading
activity in vitro, and deletion of KLK7 in AD mice resulted in
increased fibrillar Aβ pathology (Kidana et al., 2018). Further to
this, KLK7 mRNA levels were found to be reduced in AD brains
(Kidana et al., 2018).
A number of studies have also reported the ability of astrocytes
to internalize Aβ, resulting in the accumulation of Aβ1−42
within activated astrocytes (Nagele et al., 2003; Wyss-Coray
et al., 2003; Nielsen et al., 2010; Pihlaja et al., 2011). Cultured
astrocytes were shown to migrate toward C-C motif ligand 2
(CCL2), a chemokine present at AD plaques, and subsequently
bind to Aβ, although the receptors involved in in Aβ binding
were not identified (Wyss-Coray et al., 2003). ApoE deficient
astrocytes are, however, less efficient in the internalization and
degradation of Aβ deposits compared to wild-type cells, thus
implicating ApoE in astrocytic Aβ clearance (Koistinaho et al.,
2004). Moreover, in a study of AD brain tissue, Aβ present within
astrocytes was suggested to result from the phagocytosis of debris
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FIGURE 2 | Mechanism of NLRP3 activation by amyloid fibrils. A priming signal, such as LPS, leads to the increased expression of NLRP3 and precursor forms of
inflammatory cytokines IL-1β and IL-18. Aβ fibrils act as an activating stimulus via their internalization and disruption of lysosomes leading to the release of cathepsin
B into the cytosol. This is thought to trigger the assembly of the NLRP3 inflammasome complex. This complex recruits ASC adaptor protein, which forms filaments.
ASC filaments interact with pro-caspase 1 via CARD domains, resulting in caspase-1 activation. Active caspase 1 cleaves precursor forms of IL-1β and IL-18, which
are secreted from immune cells in their active form, contributing to neuroinflammation. Caspase 1 also cleaves gasdermin D, which forms pores in the cell
membrane, eventually resulting in pyroptotic cell death.
derived from damaged neurons, as neuron-specific markers were
also identified (Nagele et al., 2003).
INFLAMMASOMES AND THE CROSS
SEEDING OF Aβ AGGREGATION
A role for activated microglia in the production of
proinflammatory cytokines is well documented, and Aβ
fibrils can act as a stimulus for this activation (Halle et al., 2008;
Reed-Geaghan et al., 2009; Stewart et al., 2010). However, the
pathway for the production of pro-inflammatory cytokines IL-1β
and interleukin-18 (IL-18) in microglia may also promote Aβ
fibril formation (Venegas et al., 2017). Thus, the relationship
between microglia and Aβ is complex, and instead of attempting
to remove amyloid plaques, microglia may also be playing a role
in the formation of Aβ amyloid fibrils.
The NOD-like receptor family, pyrin domain containing 3
(NLRP3) inflammasome, is involved in the production and
release of the pro-inflammatory cytokines IL-1β and IL-18
(Swanson et al., 2019). The activation of the inflammasome
is a two-step process, requiring a priming stimulus followed
by an activating stimulus. The priming stimulus can be
cytokines, such as TNF-α and IL-1β, or pathogen associated
molecular patterns (PAMPs) such as bacterial lipopolysaccharide
(LPS) (Bauernfeind et al., 2009; Franchi et al., 2009). This
priming step results in the transcriptional upregulation of
inflammasome components, NALP3 and inactive forms of IL-
1β, IL-18 and caspase-1 (Bauernfeind et al., 2009; Franchi
et al., 2009). A number of stimuli can act as a second
activating stimulus, including ATP, pore-forming toxins that
result in low intracellular K+, crystalline structures such as
uric acid and silica, and Aβ fibrils (Mariathasan et al., 2006;
Martinon et al., 2006; Halle et al., 2008). The activating
stimulus leads to the oligomerization of NLRP3, and the
recruitment of adaptor protein apoptosis-associated speck-
like protein containing a CARD (ASC). This triggers ASC
polymerization into helical fibrils and subsequently assembly into
micrometer-sized structures known as specks (Masumoto et al.,
1999; Franklin et al., 2014; Lu et al., 2014). Caspase-1 is recruited
via a caspase recruitment (CARD) domain and this results in
caspase-1 autoproteolytic cleavage and activation. Caspase-1 is
then responsible for the cleavage and thus activation of cytokines
IL-1β and IL-18, which are released from cells, contributing to
inflammation (Figure 2).
The activation of the inflammasome by Aβ fibrils was first
shown in vitro and was dependent on Aβ phagocytosis and
the subsequent damage to lysosomes, resulting in the release
of cathepsin B into the cytosol (Halle et al., 2008). A further
study then demonstrated that when NLRP3 or caspase-1 was
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FIGURE 3 | ASC specks released from activated microglia cross-seed Aβ aggregation. The NLRP3 inflammasome is activated in microglia in response to a variety of
stimuli, including Aβ fibrils. This activation leads to the release of specks formed from ASC, an adaptor protein that is involved in the inflammasome pathway. ASC
specks cross-seed Aβ peptide, resulting in the formation of further Aβ aggregates in the brain and may create a cycle of inflammasome activation and amyloid
formation.
knocked out in transgenic AD model mice, IL-1β activation
was substantially reduced, providing support for the role of this
activation pathway in vivo (Heneka et al., 2013). Furthermore,
increased levels of cleaved caspase-1 were identified in AD patient
brains compared with controls in hippocampal and cortical
lysates, implicating the NLRP3 inflammasome as an important
pathway in disease (Heneka et al., 2013).
Crucially, in addition to the activation of the NLRP3
inflammasome by Aβ fibrils, evidence is emerging for a positive
effect of the NLRP3 inflammasome on Aβ aggregation (Figure 3).
The activation of the NLRP3 inflammasome results in the release
of ASC specks (Swanson et al., 2019). Venegas et al. (2017)
demonstrated that after their release, ASC specks bind to Aβ1−42
peptide (Venegas et al., 2017). In vitro experiments revealed
that ASC specks accelerate the aggregation of both Aβ1−40
and Aβ1−42 into oligomers and protofibrils, indicating a cross-
seeding activity (Venegas et al., 2017). This was dependent on
the PYD domain of ASC. Moreover, when purified ASC specks
were injected into the hippocampus of AD model mice, more
Aβ deposits were observed, whereas an anti-ASC-speck antibody
was capable of reducing Aβ deposition (Venegas et al., 2017).
This suggests that not only do Aβ fibrils act as a stimulus
to trigger microglial activation, but also that the result of
this activation is the formation of Aβ aggregates, effectively
producing a positive feedback loop (Figure 3). To compound
this, in the presence of ASC-Aβ composites, consisting of Aβ
oligomeric complexes forming in close association with ASC
fibrils, the phagocytic clearance of Aβ by microglia was reduced
by 35%, and its degradation was reduced (Friker et al., 2020).
Thus, the activation of the NLRP3 inflammasome by Aβ fibrils
could therefore both increase amyloid formation and reduce its
clearance, contributing to the Aβ deposition observed in AD.
ANTIMICROBIAL AND ANTIVIRAL
PROPERTIES OF Aβ AND ITS
AGGREGATION
Aβ Response to Bacteria and Fungi
Infection may be a co-factor in the aggregation of Aβ into
amyloid fibrils, moreover this may be related to the intrinsic
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antimicrobial activities of Aβ peptides. Indeed, it was found
that Aβ inhibits the growth of eight common microorganisms
including both bacterial and fungal species, at a similar potency
to the bone fide antimicrobial peptide LL-37 (Soscia et al.,
2010). A further study reported that Aβ protects against fungal
and bacterial infections in mouse, Caenorhabditis elegans and
cell culture models (Kumar et al., 2016). This was as a result
of Aβ binding to microbial cell wall polysaccharides via its
heparin-binding domain (VHHQKL) (Kumar et al., 2016). Aβ
oligomers exhibited significantly increased binding compared
to the monomeric peptide, and electron microscopy imaging
revealed Aβ fibrillation, with fibrils associating with and linking
together microbial cells into clumps, a process known as
agglutination (Kumar et al., 2016). Another study found that
this microbial agglutination was mediated by Aβ1−42, but not
Aβ1−40, suggesting that the more amyloidogenic form of this
peptide has greater antimicrobial activity (Spitzer et al., 2016).
The demonstration of the antimicrobial properties of
Aβ suggests that AD may have an infectious etiology.
A relationship has been proposed between gut microbiota
and brain amyloidosis. APP AD model mice were found to
have an altered gut microbiome compared to wild-type mice,
and when APP mice were bred under sterile conditions, a
significant reduction in cerebral Aβ pathology was observed
(Harach et al., 2017). Furthermore, fecal transplants from
APP mice bred in standard conditions to APP mice bred in
sterile conditions resulted in increased Aβ pathology, whereas
fecal transplants from wild-type mice did not have this effect
(Harach et al., 2017). This research has been supported by
studies in humans, with differences identified in the abundance
of pro- and anti-inflammatory gut bacterial taxa in patients
with brain amyloidosis (Cattaneo et al., 2017). When the
bacterial taxonomic composition of fecal samples was compared
between AD patient and control samples, a distinct microbiome
composition was identified in AD samples (Vogt et al., 2017).
Similarly, a number of studies have suggested a connection
between the oral microbiome and AD (Ide et al., 2016; Chen et al.,
2017; Dominy et al., 2019). Porphyromonas gingivalis, a pathogen
in periodontal infections, was recently identified in AD brains
and resulted in increased Aβ deposition in mice (Poole et al.,
2013; Dominy et al., 2019).
Aβ Response to Viruses
A number of studies have investigated the relationship between
viral infections and AD. There is evidence that herpes simplex
virus type-1 (HSV-1) is a risk factor for AD, when the AD
patient is a carrier of the APOE-ε4 allele (Itzhaki et al., 1997).
Subsequent studies have found an association between HSV-1
and the risk of neurodegenerative disease, with one retrospective
cohort study in Taiwan identifying a 2.56-fold increased risk
of dementia with HSV infection (Tzeng et al., 2018). However,
another study reported only a slightly increased risk (Chen
et al., 2018). In addition to HSV-1, analysis of genomic,
transcriptomic, proteomic and histopathological data from
brains identified increased human herpesvirus 6A (HHV-6A)
and human herpesvirus 7 (HHV-7) in AD brain tissue samples
compared to controls. Viral abundance was suggested to be
linked with APP metabolism networks, including the induction
of PSEN1 and BACE1 expression by HHV-6A (Readhead et al.,
2018). However, the statistical robustness of this analysis was
contested, and re-analysis of the data did not support a link
between HHV-6A or HHV-7 and AD (Jeong and Liu, 2019).
Whilst the link between herpesvirus infections and AD may
be equivocal, various studies suggest that herpesviruses and
other infectious agents promote Aβ aggregation into amyloid
fibrils. In neuronal and glial cell cultures, infection with HSV-
1 led to the accumulation of Aβ within cells, and increased Aβ
deposits were present in mouse brains after HSV-1 infection
(Wozniak et al., 2007). Further investigation revealed that in
AD, HSV-1 DNA localizes with Aβ plaques, with 90% of the
plaques containing viral DNA (Wozniak et al., 2009). Similarly,
it was shown that in a mouse model of recurrent HSV-
1 infections, AD pathologies including Aβ accumulation, tau
hyperphosphorylation and markers of neuroinflammation were
observed (De Chiara et al., 2019). These results were corroborated
recently in a 3D human brain-like model formed from human-
induced neural stem cells (Cairns et al., 2020). It was found that
whilst high HSV-1 infection levels led to cell death, low HSV-1
infection levels led to an AD-like phenotype, including dense Aβ
fibrillar plaques and neuroinflammation (Cairns et al., 2020).
Both Aβ1−40 and Aβ1−42 inhibited the replication of HSV-
1 in a number of cell lines when added to the cultures either
prior to or in parallel with the virus (Bourgade et al., 2014).
This effect was postulated to be a result of Aβ inserting into
the HSV-1 envelope (Bourgade et al., 2014). Moreover, Aβ
oligomers bind viral surface glycoproteins and fibrils mediate
virus entrapment (Eimer et al., 2018). A recent study found that
HSV-1 catalyzes the aggregation of Aβ1−42 in vitro and in an AD
mouse model via surface-mediated nucleation, thus providing
further support for this hypothesis (Ezzat et al., 2019). Crucially,
the interaction of Aβ with viruses may be the same mechanism
as its interaction with bacteria and fungi, namely the Aβ heparin-
binding domain binds carbohydrates exposed on the surface of
the virus (Eimer et al., 2018).
Not only does Aβ have antiviral activity, but its production
may be controlled by the innate immunity protein, interferon-
induced transmembrane protein 3 (IFITM3), which upregulates
the activity of γ-secretase, resulting in the increased generation of
Aβ peptide (Hur et al., 2020). Furthermore, deletion of IFITM3
in the 5xFAD mouse AD model resulted in reduced Aβ plaque
formation, and IFITM3 expression was found to increase with
aging and in mouse models expressing familial AD genes (Hur
et al., 2020). IFITM3 plays a role in preventing viral infection,
and its expression is induced by pro-inflammatory cytokines
(Bailey et al., 2014). Thus, taken together these data support
the antimicrobial and antiviral hypothesis for Aβ and suggest
that infection may be a cofactor for Aβ aggregation in vivo
(Jackson and Hewitt, 2017).
HOW TO PREVENT Aβ AGGREGATION
AND ENHANCE REMOVAL OF Aβ
DEPOSITS
Aβ plaque formation in AD will be a balance between the
rate of amyloid fibril assembly and the rate of clearance. Given
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their potential roles as cofactors in amyloid fibril assembly,
targeting microglial activation and infections by viruses and
bacteria may represent therapeutic approaches in AD. Similarly,
enhancing the uptake and degradation of Aβ fibrils may
provide an additional approach to reduce Aβ plaque burden
in AD (Figure 1).
Reducing the Activation of Microglia
Activated microglia are a characteristic feature of
neuroinflammation in AD (Frautschy et al., 1998; Felsky
et al., 2019). However, despite a decreased risk of AD
associated with long-term non-steroidal anti-inflammatory
drugs (NSAID) treatment, clinical trials of anti-inflammatory
drugs to treat AD have not yet been successful (Aisen et al.,
2003; Meyer et al., 2019; Howard et al., 2020). Minocycline,
an anti-inflammatory tetracycline capable of crossing the
blood-brain barrier (BBB), was found to reduce inflammatory
markers and reverse cognitive impairment in an AD-like
mouse model, induced by the administration of Aβ1−42
oligomers to the brain (Garcez et al., 2017). However, in
clinical trials no improvement in cognitive impairment was
identified with minocycline treatment (Howard et al., 2020).
Similarly, treatment with naproxen did not slow disease
progression in patients with mild-moderate, or reduce the
progression of pre-symptomatic AD (Aisen et al., 2003;
Meyer et al., 2019).
Whilst the aforementioned anti-inflammatories may be
ineffective in the treatment of AD, the inflammasome may prove
to be a better target. Indeed, a small molecule inhibitor of
the NLRP3 inflammasome, MCC950, was found to stimulate
Aβ phagocytosis in vitro, and reduce Aβ deposition in AD
(APP/PS1) model mice (Dempsey et al., 2017). This was
also associated with an improvement in cognitive function
(Dempsey et al., 2017). Similarly, MCC950 prevented α-synuclein
aggregate pathology and the degeneration of dopaminergic
neurons in multiple rodent models of Parkinson’s disease
(Gordon et al., 2018). These results are supported by a
study in which NLRP3 components were knocked out in
AD model mice, and this led to enhanced Aβ clearance and
decreased Aβ deposition (Heneka et al., 2013). Importantly,
these results support the clinical development of inflammasome
inhibitors as a treatment for neurodegenerative amyloid diseases
such as AD.
Targeting Viral and Bacterial Infections
The demonstration that Aβ interacts with viruses may provide
new routes of clinical intervention in AD patients; targeting
viral infection could prevent the Aβ aggregation associated
with AD. Two population cohort studies found that those
taking anti-herpetic treatments for HSV infections had a
reduced risk of dementia (Chen et al., 2018; Tzeng et al.,
2018). In addition, in a recent study in 3D brain-like
structures, HSV-1 infection induced an AD-like phenotype,
and antiviral medication was successful in abrogating this
phenotype, suggesting that antivirals could be utilized to treat
AD patients (Cairns et al., 2020). An antiviral drug, Valacyclovir,
is currently in Phase II clinical trials for the treatment of
AD (ClinicalTrials.gov, ID# NCT03282916). Similarly, targeting
bacterial infections could be used to prevent Aβ aggregation
in AD. For example, inhibition of gingipains, toxic proteases
from P. gingivalis, using small molecule inhibitors led to
reduced Aβ1−42 production, neuroinflammation and neuronal
death (Dominy et al., 2019). Consequently, a small molecule
inhibitor of gingipains, COR388, is currently in Phase II
clinical trials for the treatment of AD (ClinicalTrials.gov,
ID# NCT03823404).
Enhancing the Uptake and Degradation
of Amyloid by Microglia
Whilst a role for TLR receptors in Aβ uptake by microglia
has been suggested, these receptors also have a central role
in the activation of inflammation (Reed-Geaghan et al., 2009;
Stewart et al., 2010). Thus, targeting these receptors in the
treatment of AD is not straight forward, as a detrimental
inflammatory response could also be activated. Treatment
with an LPS-derived TLR4 agonist, monophosphoryl lipid A
(MPL) in a murine AD model led to reduced Aβ load and
enhanced cognitive function, but a ‘low level’ inflammatory
response was also triggered (Michaud et al., 2013). However,
the AAV-mediated expression of the human TLR5 ectodomain
as a ‘decoy’ receptor was explored, and found to result in
the attenuation of Aβ plaque formation in a mouse model
(Chakrabarty et al., 2018). The human TLR5 ectodomain was
fused to human IgG4 Fc (sTLR5Fc), and this was found to bind
to Aβ fibrils strongly, and to other forms of Aβ1−40 and Aβ1−42,
to lesser extents. Therefore, the reduction in Aβ deposition
into plaques could be due to the sequestration of fibrils by
the TLR5 ectodomain (Chakrabarty et al., 2018). Furthermore,
in vitro incubation with sTLR5Fc resulted in increased uptake
of Aβ1−40 fibrils by microglia without activating TLR5 signaling
(Chakrabarty et al., 2018), thus suggesting it as a safe method of
immunomodulation in AD.
TREM2 is upregulated in response to increased Aβ levels
in an AD mouse model (Jiang et al., 2014). Importantly,
upregulating TREM2 significantly reduced Aβ deposition,
neuroinflammation, synapse loss and led to improvements
in cognitive function (Jiang et al., 2014). A monoclonal
antibody targeting TREM2, AL002a, was found to activate
TREM2 signaling in vitro (Price et al., 2020). Furthermore,
treatment of 5xFAD mice with this antibody led to increased
microglial recruitment to Aβ plaques, and reduced Aβ deposition
(Price et al., 2020). TREM2 could therefore be a potential
target for clinical intervention in the treatment of AD,
and AL002 is currently being tested in Phase I clinical
trials in patients with mild to moderate Alzheimer’s disease
(ClinicalTrials.gov, ID#NCT03635047). Another monoclonal
antibody, 4D9, was recently found to increase microglial uptake
of Aβ in vitro and reduce Aβ deposits in the APP NL-G-
F knock-in AD mouse model (Schlepckow et al., 2020). This
antibody enhances TREM2 activity by competing for binding
to the α-secretase cleavage site, therefore preventing TREM2
cleavage and subsequent shedding, whilst also enhancing TREM2
signaling (Schlepckow et al., 2020).
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Macrophage colony stimulating factor (M-CSF) upregulates
the transcription of the chloride transporter CIC-7 by
microglia, increasing lysosomal acidification and enhancing
the degradation of Aβ amyloid fibrils (Majumdar et al.,
2011). This suggests that M-CSF could be used to promote
Aβ amyloid clearance in AD. Indeed, in APP(Swe)/PS1
transgenic AD model mice M-CSF treatment resulted in a
reduced number of Aβ deposits, a higher ratio of microglia
with evidence of Aβ internalization, and reduced cognitive
decline (Boissonneault et al., 2009). However, M-CSF is a
hematopoietic cytokine that has been implicated in a number of
inflammatory and autoimmune diseases and as a consequence
M-CSF treatment could have deleterious inflammatory effects
(Hamilton et al., 2016).
An alternative to enhancing pathways for fibril uptake
and degradation is to inhibit negative regulators of these
pathways. Evidence points toward a role for CD33 as a negative
modulator of Aβ fibril clearance (Bradshaw et al., 2013; Griciuc
et al., 2013, 2019), and inhibition of CD33 may represent a
therapeutic strategy. A phase I clinical trial is underway for the
monoclonal antibody, AL003, which targets and inhibits CD33
(ClinicalTrials.gov, NCT03822208). With evidence suggesting
that CD33 deletion in mice reduces Aβ pathology and increases
microglial expression of genes relating to phagocytosis, AL003
administration aims to inhibit CD33, thus increasing the
clearance activity of microglia and reducing Aβ deposition
(Griciuc et al., 2019). Similarly, CD22 could be targeted in
AD. A recent study used CRISPR-Cas9 with RNA sequencing
analysis to identify genes that are related to aging and lead
to changes in microglial phagocytosis (Pluvinage et al., 2019).
CD22 was identified as a receptor that negatively regulates
phagocytosis and is upregulated in aged microglia. It was found
that inhibiting CD22 with a CD22 blocking antibody improved
the phagocytosis of Aβ oligomers and α-synuclein fibrils in vivo,
supporting the hypothesis that AD results from age-related
changes in microglia that reduce their amyloid clearing ability
(Pluvinage et al., 2019). Similarly, manipulating microglia in
order to favor a switch from dysfunctional phenotypes to
a protective phenotype such as DAM could be a used as
future approach to restore microglial function and enhance the
clearance of Keren-Shaul et al. (2017); Krasemann et al. (2017),
and Marschallinger et al. (2020).
DISCUSSION
Multiple different cofactors may influence Aβ assembly in vivo,
including inflammation and infection. Moreover, the extent of
amyloid plaques formation in AD will be dependent on the
balance between Aβ fibril formation and the clearance and
degradation of these deposits. Evidence points to microglia
playing roles in both amyloid formation and its clearance
(Lee and Landreth, 2010; Venegas et al., 2017), as such the
balance between these microglial activities may be a factor
in the accumulation of amyloid plaques. Yet, despite their
recruitment to plaques, microglia do not appear to be able to
halt the formation Aβ fibrils in AD. In the aging AD brain a
reduction in the uptake and degradation of Aβ amyloid fibrils
by microglia may cause these cells to be overwhelmed by the
amyloid deposits (Hickman et al., 2008; Mawuenyega et al.,
2010; Krabbe et al., 2013). Enhancement of the degradative
activity of microglia therefore represent potential targets for
therapeutic intervention in AD (Boissonneault et al., 2009;
Majumdar et al., 2011).
Neuroinflammation is a damaging process in AD (Heppner
et al., 2015), but via production of the inflammasome specks
microglia could be exacerbating the disease by cross seeding
Aβ amyloid formation (Venegas et al., 2017). Moreover, Aβ
fibrils can themselves stimulate inflammasome formation and
this raises the intriguing possibility that Aβ fibrils promote
Aβ aggregation via microglia activation, resulting in a vicious
cycle (Halle et al., 2008; Heneka et al., 2013; Venegas
et al., 2017; Friker et al., 2020). As such the inflammasome
may be a good target for AD therapeutics (Heneka et al.,
2013; Dempsey et al., 2017; Gordon et al., 2018), as both
inflammation and inflammasome-dependent Aβ fibril assembly
could be reduced.
Whilst, Aβ aggregation has been thought of as being a
pathological process, Aβ has properties consistent with it being
an antimicrobial peptide (Soscia et al., 2010; Bourgade et al.,
2014; Kumar et al., 2016; Spitzer et al., 2016; Hur et al.,
2020). Indeed, there are a number of key similarities with
the antimicrobial peptide LL-37, which can also assemble into
amyloid fibrils (Sood et al., 2008; Jackson and Hewitt, 2017).
Whilst a role for Aβ in vivo as an antimicrobial peptide is
unclear, in vitro it can agglutinate viruses, bacteria and fungi
by assembling into amyloid like structures on the surface of
these infectious agents. This provides an additional mechanism
by which Aβ assembly could be promoted in vivo, by virtue
of its interaction with the surfaces of infectious agents (Kumar
et al., 2016; Eimer et al., 2018; Ezzat et al., 2019). Moreover,
infection would also be predicted to activate inflammation
and could promote Aβ aggregation via the inflammasome
(Swanson et al., 2019). Although, bacteria, fungi, viruses and
inflammasome specks can cross seed Aβ aggregation, little is
known about the structure and properties of the fibrils produced.
Crucially, both in vitro and in vivo Aβ fibrils can assemble
into multiple different fibril polymorphs, in which the Aβ
peptides have different arrangements in the fibril structure
(Petkova et al., 2005; Paravastu et al., 2008, 2009; Lu et al.,
2013; Colvin et al., 2015; Gremer et al., 2017; Kollmer et al.,
2019). Little is known about the molecular structure of the
Aβ aggregates produced by cross seeding by either specks and
microorganisms in vitro nor how they relate to those formed
in vivo in AD brain. This is important to know because Aβ
fibril polymorphism in vivo is related to the type of AD
presented (Lu et al., 2013; Qiang et al., 2017; Rasmussen
et al., 2017). Similarly, whilst Aβ fibrils can be internalized
and degraded by microglia, at least to some extent in vitro
(Husemann et al., 2001; Tahara et al., 2006; Reed-Geaghan
et al., 2009; Song et al., 2011) it is not known if polymorphism
affects clearance of amyloid fibrils in vivo. It is plausible that
Aβ fibril polymorphism could affect the affinity for microglial
Aβ receptors and how the fibrils are degraded by microglial
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proteases. Thus, any fibril polymorphs that can escape microglial
clearance may accumulate more in an AD brain.
In summary, in vivo multiple different cofactors, including
microglia and infection, may influence the assembly of Aβ
amyloid fibrils, and thus could represent targets for therapeutic
intervention in AD.
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